CN116808156A - Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof - Google Patents
Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof Download PDFInfo
- Publication number
- CN116808156A CN116808156A CN202310538764.5A CN202310538764A CN116808156A CN 116808156 A CN116808156 A CN 116808156A CN 202310538764 A CN202310538764 A CN 202310538764A CN 116808156 A CN116808156 A CN 116808156A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 51
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000003511 endothelial effect Effects 0.000 claims abstract description 19
- 230000002792 vascular Effects 0.000 claims abstract description 19
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 18
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 18
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 18
- 230000006378 damage Effects 0.000 claims abstract description 18
- 208000014674 injury Diseases 0.000 claims abstract description 18
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 17
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 17
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 16
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 16
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 16
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 16
- 235000013976 turmeric Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 241001426527 Rhaponticum Species 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 24
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 230000004900 autophagic degradation Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 8
- 230000018109 developmental process Effects 0.000 abstract description 8
- 230000004064 dysfunction Effects 0.000 abstract description 6
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract description 5
- 230000008694 endothelial dysfunction Effects 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 3
- 230000000903 blocking effect Effects 0.000 abstract description 3
- 230000004224 protection Effects 0.000 abstract description 3
- 230000006372 lipid accumulation Effects 0.000 abstract description 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 23
- 241000592183 Eidolon Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 239000002033 PVDF binder Substances 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 7
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 7
- 108700000707 bcl-2-Associated X Proteins 0.000 description 7
- 102000055102 bcl-2-Associated X Human genes 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 6
- 229960002930 sirolimus Drugs 0.000 description 6
- 102000013918 Apolipoproteins E Human genes 0.000 description 5
- 108010025628 Apolipoproteins E Proteins 0.000 description 5
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000004908 autophagic flux Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Substances C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960003764 polydatin Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-18 parts of prepared rhizoma polygonati, 9-21 parts of ganoderma lucidum, 10-30 parts of gynostemma pentaphylla, 6-18 parts of polygonum cuspidatum, 9-21 parts of radix rhaponticum, and 9-21 parts of turmeric. The invention can effectively inhibit lipid accumulation in advance in the stage of vascular endothelial injury and endothelial dysfunction without forming plaque, exert the endothelial cell protection effect, resist vascular aging and inhibit the development of atherosclerosis by blocking the vascular endothelial injury and dysfunction in the initial stage of onset.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating atherosclerosis and application of the traditional Chinese medicine composition.
Background
The pathological mechanism of atherosclerosis is fibrofatty lesions of the arterial wall, which develop progressively into atheromatous and characteristic plaques in the course of the disease. Unstable atherosclerotic plaque rupture and platelet aggregation may cause localized thrombosis, resulting in partial or total occlusion of the affected artery. Early prevention and treatment of atherosclerosis is an urgent need, vascular endothelial injury and dysfunction thereof are taken as one of key initial links and causes of atherosclerosis, and intervention and reversion of development progress thereof can be taken as an important means of atherosclerosis treatment.
In the long-term development of traditional Chinese medicine, a theoretical system mainly comprising an overall concept and treatment based on syndrome differentiation is formed, and diagnosis and treatment are performed after the overall judgment of the disease location, the etiology and the pathogenesis is performed. The treatment of vascular endothelial injury and endothelial dysfunction, which are the initiation factors of cardiovascular continuous events, is consistent with the concept of treating disease at the first place in the traditional Chinese medicine.
The prior researches prove that the traditional Chinese medicine is effective in treating atherosclerosis vascular endothelial injury and dysfunction. Can control dangerous factors, and has the functions of resisting inflammation, resisting oxidation, improving endothelial steady-state environment and the like. However, the prevention and treatment of atherosclerosis is still in the primary stage of controlling risk factors such as hypertension, hyperlipidemia and the like, and the research of inhibiting and even reversing vascular endothelial injury, preventing plaque generation and cutting off the development and development path of atherosclerosis is less in time in the initial link. Most of the existing researches stay in clinical index stage, lack of mechanism research of a complete system, and have less related symptoms and adaptation indexes.
The current research suggests that the traditional Chinese medicine Luhuang particles consist of prepared fleece flower root, prepared rhizoma polygonati, turmeric, safflower, giant knotweed and uniflower swisscentaury root, and have the effects of tonifying liver and kidney, promoting blood circulation and removing blood stasis. And results in clinical studies have demonstrated that they reduce plaque, reduce inflammation and thereby inhibit the progression of atherosclerosis. However, the Luhuang granule has more warm drugs, is easy to cause the fluctuation of blood pressure of patients, and is easy to generate clinical response of thermal symptoms of excessive warm supplementation.
Disclosure of Invention
Aiming at the defects and shortcomings in the prior art, the invention aims to provide a traditional Chinese medicine composition for preventing and treating atherosclerosis, which is prepared by extracting effective components from a plurality of traditional Chinese medicines and is superior to the existing clinical common medicines in the aspects of reducing blood fat, protecting vascular endothelial injury and dysfunction and promoting autophagy to inhibit endothelial cell apoptosis.
The invention also aims at providing the application of the traditional Chinese medicine composition.
The technical scheme of the invention is as follows:
the traditional Chinese medicine composition for preventing and treating atherosclerosis is characterized by comprising the following raw materials in parts by weight: 6-18 parts of prepared rhizoma polygonati, 9-21 parts of ganoderma lucidum, 10-30 parts of gynostemma pentaphylla, 6-18 parts of polygonum cuspidatum, 9-21 parts of radix rhaponticum, and 9-21 parts of turmeric.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-18 parts of prepared rhizoma polygonati, 12-18 parts of ganoderma lucidum, 28-30 parts of gynostemma pentaphylla, 12-18 parts of polygonum cuspidatum, 12-18 parts of radix rhaponticum, and 12-18 parts of turmeric.
Further, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric.
Further, the traditional Chinese medicine composition is in any one of decoction, granules, traditional Chinese medicine ointment and honeyed pills.
Furthermore, the traditional Chinese medicine composition is in the form of granules or decoction.
The application of the traditional Chinese medicine composition in preparing medicines for preventing and treating atherosclerosis.
Further, the Chinese medicinal composition protects vascular endothelial injury and inhibits growth of atherosclerotic plaques by inducing autophagy and reducing apoptosis.
Further, the atherosclerosis is early atherosclerosis.
Compared with the prior art, the invention has the following advantages:
(1) The traditional Chinese medicine composition (namely the eidolon particles) for preventing and treating atherosclerosis can effectively relieve the elastic hardness of arteries in advance in the stage that vascular endothelial injury and endothelial dysfunction do not form plaque, overcomes the dangerous factors such as vascular aging and various biochemical indexes, and inhibits the development of atherosclerosis by blocking the early vascular endothelial injury and dysfunction.
Based on the above, combining with clinical experience, we put forward a theory of pulse loss, which takes the vascular endothelial injury and endothelial dysfunction as initial factors as an access point, and provides a preliminary clinical theoretical basis for the prevention and treatment of atherosclerosis by protecting the vascular endothelial injury and dysfunction of the eidolon particles. Furthermore, it was found in research that the particles of the eidolon can alleviate the progression of atherosclerosis, in particular, the particles of the eidolon protect endothelial injury and inhibit the growth of atherosclerotic plaques by inducing autophagy and reducing apoptosis. The change of autophagy function can influence the apoptosis outcome as an incision point, and the effect target point and mechanism for treating the relevance of the apoptosis outcome in treating atherosclerosis vascular endothelial injury and cutting off the development path of atherosclerosis are clear; the improvement of vascular endothelial injury and endothelial dysfunction by regulating autophagy flux has been well established against atherosclerosis.
(2) The invention relates to a traditional Chinese medicine composition for preventing and treating atherosclerosis, namely, a genipin granule, which is prepared from rhizoma polygonati, ganoderma lucidum, gynostemma pentaphylla, turmeric, polygonum cuspidatum and uniflower swisscentaury root. The prescription is simple, and the medicine is less in work. The treatment principle is that 'qi-tonifying yin-nourishing, heat-clearing and detoxicating, blood-activating and phlegm-resolving'. Modern pharmacological researches show that rhizoma polygonati has various biological activities such as oxidation resistance, aging resistance, osteoporosis resistance, neuroprotection, immunity enhancement, diabetes resistance, cancer resistance and the like, and inflammatory cytokines can be reduced by promoting the expression of Nuclear factor-related factor 2 (Nrf 2) to play an anti-inflammatory role; the active ingredient ganoderic acid A of the ganoderma lucidum has the effects of protecting liver, protecting nerves, resisting hepatitis, reducing cholesterol, resisting histamine, resisting tumor and the like, can improve liver steatosis and hyperlipidemia induced by high-fat diet, regulate intestinal microbiota composition and reduce the risks of atherosclerosis and cardiovascular diseases; the gynostemma pentaphylla total saponin can reduce inflammatory heart injury by inhibiting activation of a cell nuclear factor/K gene binding nuclear factor (Transcription factor p, NF-kB p 65) through a MAPK signal pathway in an H9C2 cell model; the radix Rhapontici ethanol extract can effectively inhibit the production of inflammatory mediators such as nitric oxide, nitric oxide synthase, inflammatory cytokines and epoxide enzyme 2, and exert anti-inflammatory activity; the polydatin and curcumin have wide biological activities of anti-inflammatory, anti-oxidative stress and the like, thereby playing an anti-AS role.
Aiming at the early atherosclerosis with deficiency of vital energy, rhizoma polygonati and lucid ganoderma are used for nourishing liver and kidney, so as to greatly tonify primordial qi, and qi and blood flow; curcuma rhizome and rhizoma Polygoni Cuspidati are used for promoting blood circulation; it is combined with Gynostemma Pentaphyllum and radix Rhapontici to clear away the toxic materials.
(3) Compared with the existing Chinese medicine Luhuang granule, the gynostemma pentaphylla and the ganoderma lucidum in the eidolon granule have more remarkable effects of clearing heat and detoxicating, nourishing heart and tranquillizing, tonifying qi and producing sperm.
Drawings
FIG. 1 shows ApoE in the examples -/- Schematic of serum LDL-C levels in mice; (n=3, ## p<0.01vs.Control group； * p<0.05, ** p<0.01vs.the Model group；one-way ANOVA.)。
FIG. 2 is an ApoE of the examples -/- Schematic of serum TC levels in mice; (n=3, ## p<0.01vs.Control group； * p<0.05, ** p<0.01vs.the Model group；one-way ANOVA.)。
FIG. 3 is an ApoE of the examples -/- Mouse aortic frozen section LC3A/B immunofluorescent staining: (A) mouse aortic tissue LC3A/B immunofluorescent staining; (B) LC3A/B expression level in mouse aortic tissue; (n=3, ** p<0.01vs.the Model group；one-way ANOVA.)。
FIG. 4 shows Western Blot protein expression of APOE-/-mouse aortic apoptosis proteins in examples: (A) Immunoblotting images of the aortic tissue of mice, clear-Caspase 3, bax and Bcl-2; (B) Bax expression level in aortic tissue of mice; (C) clear-Caspase 3 expression level in aortic tissue of mice; (D) Bcl-2 expression level in aortic tissue of mice (n=3, # p<0.05, ## p<0.01vs.Control group； ** p<0.01vs.the Model group；one-way ANOVA.)。
Detailed Description
The invention is further described below with reference to examples and figures.
EXAMPLE 1-N preparation of the Chinese medicinal composition of the invention
Example 1: elfin granule water decoction
Taking materials according to the following proportion: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric.
The preparation method of the eidolon granule water decoction of the embodiment comprises the following steps:
1. weighing the raw materials according to the proportion, removing impurities, cleaning, sun drying or baking.
2.300ml of drinking water is soaked for 20-30 minutes, the water surface is soaked for about 2-3 cm, the temperature is regulated to be within the range of 60-80 ℃ for 10-15 minutes after the first boiling, the liquid medicine is poured out for 150-200 ml, then a proper amount of water is heated for the second time, the boiling temperature is kept within the range of 60-80 ℃, 150-200 ml of liquid medicine is poured out, and the two liquid medicines are mixed, thus obtaining the eidolon granule water decoction.
Example 2: elfin granule
Taking materials according to the following proportion: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric.
The preparation method of the eidolon granule of the embodiment is as follows:
1. weighing the raw materials according to the proportion, removing impurities, cleaning, sun drying or baking.
2. Powdering: mixing the above raw materials, and then sequentially crushing, primary grinding and secondary grinding to obtain traditional Chinese medicine composition particles;
3. preparing: and adding the traditional Chinese medicine composition particles into water with the temperature of 40-50 ℃ for dissolving for 10 minutes, thus obtaining the eidolon granule.
Alternatively, the preparation method of the eidolon granule of this embodiment is as follows: directly preparing 10 parts of rhizoma polygonati particles, 15 parts of ganoderma lucidum particles, 30 parts of gynostemma pentaphylla particles, 15 parts of polygonum cuspidatum particles, 15 parts of radix Rhapontici particles and 15 parts of turmeric particles from a pharmacy, mixing the above materials, and adding the mixture into water at 40-50 ℃ to dissolve for 10 minutes to obtain the eidolon particles.
Example 3: elfin granule
The rest is the same as in example 2, provided that the raw material proportions are different: 6 parts of prepared rhizoma polygonati, 9 parts of ganoderma lucidum, 28 parts of gynostemma pentaphylla, 12 parts of polygonum cuspidatum, 21 parts of uniflower swisscentaury root and 21 parts of turmeric.
Example 4: elfin granule paste
Taking materials according to the following proportion: 18 parts of prepared rhizoma polygonati, 18 parts of ganoderma lucidum, 10 parts of gynostemma pentaphylla, 6 parts of polygonum cuspidatum, 9 parts of uniflower swisscentaury root and 9 parts of turmeric.
The preparation method of the eidolon granule paste of the present embodiment is as follows:
1. weighing the raw materials according to the proportion, removing impurities, cleaning, sun-drying or oven-drying for standby.
2. Mashing the above materials into powder. Filtering with 100 mesh sieve to obtain mixture.
3. Adding 1500ml of drinking water, soaking for 8 hours, boiling with strong fire, and decocting with slow fire for 2 hours; decocting with slow fire for 2h and 1h with water amount of 1000ml and 800ml respectively; and after the decoction is finished, filtering, and combining the filtrates. Adding colla Corii Asini, sucrose and Mel adjuvants, mixing, and concentrating to obtain soft extract with density of 1.5-1.6.
The administration method of the ointment comprises the following steps: is taken once in the morning and evening, and is taken with 50 to 100ml of warm water each time.
Test example:
1. medicament
The eidolon pellet water decoction of example 1 was thawed in sterile water and equivalent dose conversion was performed on body weight and body surface area to determine dose concentration for animal models.
2. Animal experiment
2.1 experimental grouping and animal model preparation:
ApoE 5 weeks old -/- After one week of adaptive feeding of mice (purchased from Jiangsu Jiuzhikang biotechnology Co., ltd.), the mice were randomly divided into 5 groups (n=8) including a hyperlipidemia Model group (Model), a Rapamycin group (Rapamycin), a low dose of eimers granule group (JLG) low ) And high dose group of eidolon particles (JLG high ) And (3) feeding with high-fat feed.
C57BL/6 mice (purchased from Jiangsu Jiuyaokang biotechnology Co., ltd.) were fed as a normal Control group (Control), normal feed.
ApoE is adopted in hyperlipidemia model group -/- Mice were established and fed with high fat diet for 11 weeks with free moisture intake, and weight changes were weighed once a week. After one week of high fat modeling, different doses of drug (in terms of equivalent doses for humans and animals) were administered: the low dose group of puck particles (0.11 g/10 g/d), the high dose group of puck particles (0.22 g/10 g/d) and the rapamycin group (4 mg/kg/d) were administered intragastrically for a total of 10 weeks. After the last dose, the mice are fasted for 12 hours without water inhibition, and serum samples and aorta samples of the mice are respectively collected for detection after anesthesia.
2.2, material selection:
after 10 weeks of drug intervention, mice were fasted for 12 hours and the isoflurane was inhaled for anesthesia to remove the eyeball for blood collection. Placing the sample into a standing table for standing for 1.4h, centrifuging (4000 rpm at 4 ℃) for 16min, sucking the upper serum, and placing into a refrigerator at minus 80 ℃ for preservation. After blood collection, the thoracic cavity is cut off, the whole aorta is separated from the back wall of the thoracic cavity, the adventitia adipose tissue is peeled off under a stereoscopic microscope, and then the aorta is placed in a freezing tube, quickly frozen in liquid nitrogen and stored in an environment of minus 80 ℃ for later experiments.
2.3 Experimental methods
2.3.1 blood lipid level detection
TC and LDL-C (total cholesterol and low density lipoprotein) in serum are detected by a full-automatic biochemical analyzer.
2.3.2 LC3A/B immunofluorescent staining of aortic frozen sections
The aortic root sections were frozen and fixed with 4% paraformaldehyde for 20 minutes followed by permeation for 30 minutes using 0.5% triton X-100. The sections were then blocked with 2% BSA for 1 hour, and incubated overnight at 4℃with LC3A/B (1:150) primary antibody. After 3 washes with TBST (TBS solution with 0.1% Tween-20) the next day, sections were incubated with Alexa Fluor 488/555 conjugated secondary antibody for 2 hours at room temperature. TBST was washed 3 times and DAPI solution was added to stain nuclei. Observed and photographed by a laser confocal microscope, the excitation wavelengths were 488 nm and 555 nm. Quantitative analysis was performed using ImageJ software and the protein of interest was normalized to DAPI fluorescence intensity.
The 2.3.3Western blot method detects the expression level of clear-Caspase 3, bax and Bcl-2 proteins in aortic tissues.
The method comprises the following specific operation steps.
2.3.3.1 protein extraction and quantification
(1) Taking out the frozen tissue, selecting a reagent kit instruction of a protein quantification kit (BCA method) for protein cleavage extraction, centrifuging the cleaved sample at 1000rpm at 4 ℃ for 10min, and packaging for later use, thereby avoiding repeated freeze thawing.
(2) Protein concentration was determined by BCA method, the remaining samples were adjusted by adding an equal volume of water and SDS-PAGE buffer 5x, and denatured by boiling at 100 ℃ for 5 minutes.
2.3.3.2SDS-PAGE gel preparation
According to the molecular weight of the target protein, 10%, 12%, 8% of the separation Gel and 5% of the concentration Gel were prepared according to the SDS-PAGE Gel Kit.
2.3.3.3SDS-PAGE gel electrophoresis
(1) And the loading amount of the protein sample to be detected is 40 micrograms.
(2) Electrophoresis conditions, wherein the concentration gel has constant pressure of 80V and about 40min; the separation gel was subjected to constant pressure 120V and electrophoresis until bromophenol blue reached the bottom of the gel.
2.3.3.4 gel transfer film
(1) Soaking a PVDF film with proper size in methanol for 30s, transferring the PVDF film into WB transfer buffer solution, preparing two pieces of filter paper with the same thickness as the PVDF film, and soaking the filter paper in the transfer solution for later use; excess gel was partially excised and placed in the foam-cushion sandwich in the order filter paper, gel, PVDF membrane, filter paper to eliminate air bubbles as much as possible. Setting the current as 300mA constant current film; PVDF membrane with 0.22 μm aperture, and membrane transferring time of 1-2h.
(2) Sealing, namely soaking the PVDF film into sealing liquid after the transfer is finished, and gently shaking the PVDF film in the middle of a shaking table for 1h.
(3) And 7, primary antibody incubation, namely placing the PVDF membrane into an antibody incubation box after the end of blocking, adding the prepared primary antibody, and incubating at 4 ℃ overnight.
(4) And (3) washing the membrane by TBST for 5 minutes each time.
(5) Secondary antibody incubation, namely adding secondary antibody (Anti-rabit IgG (H+L) 1:5000 for dilution), and carrying out shaking table incubation at room temperature for 50 minutes.
(6) And (3) washing the membrane, namely washing the membrane by TBST for 4 times, wherein each time is 5 minutes.
(7) And exposing, namely soaking the washed PVDF film in ECL hypersensitive luminous liquid, tiling in a cassette, developing and fixing.
2.3.3.5 results processing
The band gray values were read using Image J software. The relative expression level of the apoptosis-related protein is obtained by calculating the ratio of the gray values of the protein of interest and β -actin.
3. Experimental results
(1) As shown in FIGS. 1 and 2, there was a reduction in LDL-C, TC levels in serum of Model mice after treatment with the Elfin particles compared to Model groups (p<0.01)。JLG high The group decreased LDL-C and TC more effectively than the Rapamycin group.
(2) As shown in FIG. 3, analysis of LC3A/B fluorescence area with image J software and quantification showed significant up-regulation of expression of LC3A/B in the Elfin granule intervention group compared to the Model group (P < 0.01).
(3) To determine whether the protective effect of the inventive eidolon particles in a vascular endothelial injury model was associated with its effects on autophagy function altering apoptosis levels. We continued to examine the expression of the apoptosis marker proteins clear-Caspase 3 and Bax, bcl-2, and the results are shown in FIG. 4.
FIG. 4A shows that the expression of the pro-apoptotic proteins clear-Caspase 3, bax was enhanced and the expression of the anti-apoptotic protein Bcl-2 was reduced (P < 0.05) in the Model group compared to the Control group. The JLG group and the Rapamycin group showed reduced clear-Caspase 3 expression and increased Bcl-2 expression compared to the Model group. Meanwhile, JLG group Bax expression was inhibited, whereas the effect of Rapamycin on Bax expression was not significant (P < 0.01).
The above results show that the high-fat diet induced vascular endothelial injury model has a phenomenon of increased autophagy flux and decreased apoptosis response. And this result is positively altered by intervention of the eidolon particles, i.e. the eidolon particles exert an anti-apoptotic effect by promoting autophagy. Thus, it was confirmed that the eidolon particles delay the development of AS by promoting autophagy to alleviate vascular endothelial cell damage caused by lipid accumulation.
Actual case comparison:
1. case selection:
100 patients meeting the inclusion standard, which are treated in the department of cardiology department of the affiliated hospital of the university of Nanjing traditional Chinese medicine, are selected from 10 months 2019 to 6 months 2021, and are divided into 50 patients in a test group and a control group by adopting a random digital table method, 96 patients are completed, and 2 patients fall off from the control group (1 lost visit, 1 patient has insufficient drug treatment course); test groups shed 2 cases (all due to loss of access). Of 96 cases meeting the standard, 48 cases of control group, 20 cases of male and 28 cases of female, the average age (47.54 + -10.47) years old, the average height (1.67+ -0.08) m, the average body mass (68.23+ -11.36) kg, the average BMI (24.38+ -3.06) kg.m-2, 25 cases of hypertension history, 3 cases of diabetes, 10 cases of smoking and 11 cases of drinking; the test group consisted of 48 cases, 22 cases, 26 cases, average age (47.60 + -9.59), average height (1.66+ -0.06) m, average body mass (66.84 + -9.22) kg, average BMI (24.07+ -2.44) kg.m-2, 30 cases with history of hypertension, 3 cases with diabetes, 15 cases with smoking, and 12 cases with drinking. The comparison difference of the baseline data of the 2 groups of patients has no statistical significance (P > 0.05), and the baseline is balanced and comparable.
2. The intervention method comprises the following steps:
atorvastatin (specification: 10 mg/tablet) was administered orally 1 time a day, 1 tablet at a time, to the control group. The test group took the granules of the eidolon granules of example 2 on the basis of the control group, with water, 1 time a day, 1 pack each time.
3. Results:
table 1 comparison of blood lipid levels before and after treatment of patients
As can be seen from Table 1, both the control and test groups improved the levels of LDL-C, TC, TG in the patients and reduced the risk of developing atherosclerotic cardiovascular disease in the patients. The test group combines the genipin to further reduce the TC level on the basis of the atorvastatin, which shows that the genipin can further regulate the blood fat level of patients.
TABLE 2 comparison of haemorheology indicators before and after treatment of patients
As can be seen from Table 2, the 2 sets of interventions all improve the blood flow hypo-cut level of the patient, which reduces the blood plasma viscosity value, while the eidolon particles further reduce the blood flow hypo-cut level of the patient, improving the blood rheology of the patient.
In addition, two typical cases are listed below for reference.
Typical case 1:
feng Mou A patient is aged 58 years, and the patient has the symptoms of high blood lipid (TC: 5.65mmol/L, LDL-C:3.17 mmol/L), yellowish urine, loose stool, pale tongue with teeth marks, thin and yellow tongue coating, and deep and wiry pulse. Carotid color ultrasound: bilateral carotid atherosclerosis is accompanied by plaque formation. Western diagnosis: hyperlipidemia, atherosclerosis. Diagnosis of traditional Chinese medicine: dizziness (hyperactivity of liver yang). Prescription: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric. The granules of example 2 were orally administered. Two diagnoses: the blood lipid test results show that: TC 4.82mmol/L and LDL-C2.45 mmol/L. After the modification of the formula is continued for 2 months, biochemical indexes such as blood fat and the like are improved, which indicates that the medicine is effective and has no obvious toxic or side effect.
Typical case 2:
in a certain period, men, 50 years old, were physically examined to find an increase in blood pressure, and the precordial pain was intercropped for two years, and had an episode of more than 20 days. Normal urine, loose stool, broken teeth on the pale tongue, thin and yellow coating, and thin and wiry pulse. The blood lipid test results show that: TC 5.44mmol/L and LDL-C3.23 mmol/L. Liver, gall, pancreas and spleen color Doppler ultrasound: fatty liver. Carotid color ultrasound: bilateral carotid atherosclerosis is accompanied by left plaque formation. Western diagnosis: hyperlipidemia, atherosclerosis. Diagnosis of traditional Chinese medicine: dizziness (hyperactivity of liver yang). Prescription: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric. The granules of example 2 were orally administered. Two diagnoses: the results of the blood lipid test showed that TC was 4.79mmol/L and LDL-C was 2.61mmol/L. After the modification of the formula is continued for 2 months, biochemical indexes such as blood fat and the like are improved, which indicates that the medicine is effective and has no obvious toxic or side effect.
The above embodiments are only for illustrating the technical idea of the present invention, and the protection scope of the present invention is not limited thereto, and any modification made on the basis of the technical scheme according to the technical idea of the present invention falls within the protection scope of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for preventing and treating atherosclerosis is characterized by comprising the following raw materials in parts by weight: 6-18 parts of prepared rhizoma polygonati, 9-21 parts of ganoderma lucidum, 10-30 parts of gynostemma pentaphylla, 6-18 parts of polygonum cuspidatum, 9-21 parts of radix rhaponticum, and 9-21 parts of turmeric.
2. The traditional Chinese medicine composition for preventing and treating atherosclerosis according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-18 parts of prepared rhizoma polygonati, 12-18 parts of ganoderma lucidum, 28-30 parts of gynostemma pentaphylla, 12-18 parts of polygonum cuspidatum, 12-18 parts of radix rhaponticum, and 12-18 parts of turmeric.
3. The traditional Chinese medicine composition for preventing and treating atherosclerosis according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 parts of prepared rhizoma polygonati, 15 parts of ganoderma lucidum, 30 parts of gynostemma pentaphylla, 15 parts of polygonum cuspidatum, 15 parts of uniflower swisscentaury root and 15 parts of turmeric.
4. A traditional Chinese medicine composition for preventing and treating atherosclerosis according to any one of claims 1-3, wherein the traditional Chinese medicine composition is in the form of any one of decoction, granule, traditional Chinese medicine ointment and honeyed pill.
5. The traditional Chinese medicine composition for preventing and treating atherosclerosis according to claim 4, wherein the dosage form of the traditional Chinese medicine composition is granules or decoction.
6. Use of the Chinese medicinal composition according to any one of claims 1-5 for the preparation of a medicament for the prevention and treatment of atherosclerosis.
7. The use according to claim 5, wherein the Chinese medicinal composition protects vascular endothelial injury and inhibits growth of atherosclerotic plaques by inducing autophagy and reducing apoptosis.
8. The use according to claim 6 or 7, wherein the atherosclerosis is early atherosclerosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310538764.5A CN116808156A (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310538764.5A CN116808156A (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116808156A true CN116808156A (en) | 2023-09-29 |
Family
ID=88121252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310538764.5A Pending CN116808156A (en) | 2023-05-15 | 2023-05-15 | Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116808156A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727820A (en) * | 2011-04-08 | 2012-10-17 | 温凯翔 | Fermented traditional Chinese medicine for treating hyperlipidemia and fatty liver and preparation method thereof |
| CN104906251A (en) * | 2015-07-10 | 2015-09-16 | 江苏省中医院 | Traditional Chinese medicine compound combination with diabetes treating effect and preparation method and application thereof |
-
2023
- 2023-05-15 CN CN202310538764.5A patent/CN116808156A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727820A (en) * | 2011-04-08 | 2012-10-17 | 温凯翔 | Fermented traditional Chinese medicine for treating hyperlipidemia and fatty liver and preparation method thereof |
| CN104906251A (en) * | 2015-07-10 | 2015-09-16 | 江苏省中医院 | Traditional Chinese medicine compound combination with diabetes treating effect and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘春玲;等: "芦黄颗粒对实验性动脉粥样硬化家兔C反应蛋白和白细胞介素-6水平的影响", 中国中西医结合急救杂志, vol. 12, no. 06, 28 November 2005 (2005-11-28), pages 366 - 368 * |
| 王雨涵;等: "基于" 脉损" 学说辨治早期动脉粥样硬化", 北京中医药大学学报, vol. 46, no. 02, 28 February 2023 (2023-02-28), pages 186 - 190 * |
| 王露;等: "中西药联用治疗肝肾亏虚、痰瘀阻络型动脉粥样硬化20例临床研究", 江苏中医药, vol. 48, no. 08, 5 August 2016 (2016-08-05), pages 24 - 26 * |
| 龚帆影;等: "精灵颗粒对动脉粥样硬化患者血管弹性功能影响的临床研究", 南京中医药大学学报, vol. 38, no. 09, 30 September 2022 (2022-09-30), pages 805 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516543A (en) | Composition for prevention and treatment of liver disease comprising ginseng polysaccharide extract | |
| EP2149379B1 (en) | Use of a vegetable drug composition in the manufacturing of a pharmaceutical preparation for the treatment of portal hypertension caused by hepatocirrhosis | |
| WO2012050735A1 (en) | Methods and dosage forms for the treatment of human cancers | |
| JP6355689B2 (en) | Pharmaceutical composition for preventing or treating liver fibrosis or non-alcoholic fatty liver | |
| WO2017181857A1 (en) | Composition for fat reduction and liver protection, and application thereof | |
| CN1513447A (en) | Application of bamboo leaf total flavone in medicine for treating and preventing prostata disease and health-care-food | |
| CN116808156A (en) | Traditional Chinese medicine composition for preventing and treating atherosclerosis and application thereof | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN104840494A (en) | Use of penthorum chinense pursh extract in preparing medicines for treating hepatitis c | |
| CN104784670A (en) | Pharmaceutical composition for treating myocarditis and preparation method of pharmaceutical composition | |
| KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
| CN111375022B (en) | Traditional Chinese medicine composition for treating prostatic hyperplasia | |
| KR102192586B1 (en) | Phamaceutical composition for treating fatty liver disease and health functional for improving liver function comprising extracts or powder of Pleurotus eryngii var. ferulea (Pf.) | |
| CN111202775B (en) | Medicine for treating non-alcoholic fatty liver disease and preparation method thereof | |
| CN108159337A (en) | Treat the pharmaceutical composition of viral liver disease | |
| CN107625796B (en) | Pharmaceutical composition containing radix angelicae and application thereof | |
| CN111032067A (en) | Sanguisorbae radix extract for treating fatty liver disease | |
| WO2024119622A1 (en) | Use of mulberry extract in preparation of drug for preventing and/or treating hepatobiliary diseases | |
| JP2011032256A (en) | Pharmaceutical composition and health food, produced by prevention of mengen reaction occurring at the time of taking saponin-containing galenical such as medicinal carrot and by process for increasing absorptivity of crude drug (method for causing chicken egg protein to absorb active constituent of galenical) | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| KR102475985B1 (en) | Composition for preventing or treating rheumatoid arthritis comprising combination extract containing Rhei Rhizoma, Scutellariae Radix and Coptidis Rhizoma | |
| CN104069173B (en) | Treat pharmaceutical composition of liver diseases and preparation method thereof | |
| KR102633837B1 (en) | Method for preparing mixture of Scutellariae Radix extract and Coptidis Rhizoma extract having excellent improvement and treatment for rheumatoid arthritis, and composition for preventing or treating rheumatoid arthritis comprising thereof | |
| CN111298061B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof | |
| JP2003206233A (en) | Health food for patient with chronic hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |